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Abstract  
Accumulating data suggest that diets rich in flavanols and procyanidins are beneficial for 
human health. In this context, there has been a great interest in elucidating the systemic 
levels and metabolic profiles at which these compounds occur in humans. While recent 
progress has been made, there still exist considerable differences and various 
disagreements with regard to the mammalian metabolites of these compounds, which in 
turn is largely a consequence of the lack of availability of authentic standards that would 
allow for the directed development and validation of expedient analytical methodologies. 
In the present study, we developed a method for the analysis of structurally-related 
flavanol metabolites using a wide range of authentic standards. Applying this method in 
the context of a human dietary intervention study using comprehensively characterized 
and standardized flavanol- and procyanidin-containing cocoa, we were able to identify 
the structurally-related (−)-epicatechin metabolites (SREM) postprandially extant in the 
systemic circulation of humans. Our results demonstrate that (−)-epicatechin-3′--D-
glucuronide, (−)-epicatechin-3′-sulfate, and a 3′-O-methyl(−)-epicatechin-5/7-sulfate are 
the predominant SREM in humans, and further confirm the relevance of the 
stereochemical configuration in the context of flavanol metabolism. In addition, we also 
identified plausible causes for the previously reported discrepancies regarding flavanol 
metabolism, consisting to a significant extent of inter-laboratory differences in sample 
preparation (enzymatic treatment and sample conditioning for HPLC analysis) and 
detection systems. Thus, these findings may also aid in the establishment of consensus 
on this topic. 
 
Keywords 
epicatechin, metabolism, flavanols, polyphenols, flavonoids 
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List of abbreviations 
BW: body weight; SPE: solid-phase extraction; UVD: ultraviolet absorbance detection; 
FLD: fluorescence detection; ECD: electrochemical detection; MS: mass spectroscopy; 
aSL: aryl-sulfatase; GL:  -glucuronidase; UGT: UDP-glucuronosyltransferase; SREM: 
structurally-related (−)-epicatechin metabolites; SULT: sulfotransferase; COMT: catechol 
O-methyl transferase. 
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Introduction 
Flavanols and their oligomeric derivatives, the procyanidins, belong to a subclass 
of flavonoids widely present in the human diet; particularly in food and beverages like 
tea, wine, cocoa, apple, plums, pomegranate and berries [1-3]. Accumulating data from 
medical anthropological [4], epidemiological [5-7], and dietary intervention studies [8-15] 
support the notion that the consumption of diets rich in flavanols and procyanidins 
decrease the incidence of morbidity and mortality from cardiovascular diseases. This 
concept has been further substantiated by recent studies demonstrating that the 
presence of individual flavanols, such as (−)-epicatechin, in food can, at least in part, be 
causally linked to the beneficial vascular effects observed after consumption of flavanol 
and procyanidin-containing foods [16-18]. In this context, there is an increasing interest 
in elucidating the mechanisms by which the consumption of these compounds, in 
particular (−)-epicatechin, mediates the observed effects [19]. However, ingested (−)-
epicatechin is metabolized into a wide range of metabolites, including structurally-related 
(−)-epicatechin metabolites (SREM), which maintain an intact flavanol ring, and ring-
fission metabolites, originating from (−)-epicatechin breakdown by gut microbiome. 
Therefore, it is essential to elucidate the specific chemical structures and levels of (−)-
epicatechin metabolites that are systemically present in humans, as these metabolic 
derivatives may represent the molecules actually eliciting the effects observed after (−)-
epicatechin consumption [17, 18]. In this context, and considering that the vascular 
effects observed after (−)-epicatechin intake are temporally and quantitatively correlated 
with SREM in circulation [17, 18], establishing the chemical structure of this particular 
group of metabolites is critical. 
There are several studies that reported on the absorption and metabolism of (−)-
epicatechin in humans and other mammalian species [17, 20-24]. Thus far, it has been 
clearly established that ingested (−)-epicatechin is extensively metabolized into SREM 
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by O-methylation, O-sulfonation, O-glucuronidation, and combinations thereof [25-28]. 
Consequently, the potential postprandial profile of SREM is of considerable broadness 
with regard to the properties of its individual constituents in terms of chemical structure, 
molecular charge, molecular mass, lipophilicity, acidity, chemical reactivity, protein-
binding capacity, and others. Thus, it may not be surprising that there exist 
discrepancies in the literature with regard to the precise structure and abundance of the 
main SREM systemically present in humans [17, 21, 23]. While several factors can be 
postulated to contribute to these discrepancies (e.g. food matrix effects on absorption, 
intake amount-dependent differences, inter-individual variations, etc.), at this point in 
time, a significant part of the underlying causes for this issue may essentially lie in 
methodological differences, such as sample preparation and chromatographic analyses. 
Current sample preparation and conditioning methods vary greatly across different 
studies [24, 25, 29-33], as do the chromatography and detection systems [23, 33, 34]. 
Consequently, when considering the broadness of the potential SREM, the wide-ranging 
inter-laboratory differences in sample preparation and analytical methods may represent 
a key contributing factor for the substantial differences with regard to the reported levels 
and relative abundance of particular metabolites. This argument is further supported 
when considering that none of the currently published methods of either sample 
preparation or chromatography was validated against an array of authentic standards 
that reflects the postprandial SREM in terms of its broad range of physicochemical 
properties. Consequently, the numerical values for systemic levels of SREM that are 
currently reported in the literature carry a significant burden of uncertainty. On the 
surface this issue may seem of a somewhat specialized technical nature, but on the 
contrary, the correct identification of (−)-epicatechin metabolites and their consistent and 
accurate measurement across different investigator groups is essential not only for 
characterizing and elucidating the potential metabolites driving (−)-epicatechin-mediated 
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bioactivities in humans, but for meaningfully assessing dietary intake, investigating 
cause-effect relationships with regard to potential health benefits, and thus for ultimately 
translating our collective knowledge into recommendations for primary and secondary 
prevention, dietary guidelines, and public health. 
In the present study, using a wide range of de novo chemically synthesized 
authentic (−)-epicatechin metabolite standards, we developed a method to assess the 
postprandial profile of SREM extant in the systemic circulation of humans. This 
methodology was subsequently applied in the context of a controlled dietary intervention 
study in healthy male adult volunteers. The results obtained were evaluated and 
discussed in the context of previous data. 
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Materials and Methods 
Materials 
Authentic, chemically de novo synthesized (−)-epicatechin metabolite standards, 
including 3′-O-methyl(−)epicatechin, 4′-O-methyl(−)epicatechin, and the ammonium salts 
of (−)-epicatechin-4′­sulfate, (−)-epicatechin-3′­sulfate, (−)-epicatechin-5­sulfate, (−)-
epicatechin-7­sulfate, (−)-epicatechin-7--D-glucuronide, (−)-epicatechin-3′--D-
glucuronide, 3′­O-methyl(−)-epicatechin-7--D-glucuronide, 4′­O­methyl(−)-epicatechin-
5--D-glucuronide, 4′­O­methyl(−)-epicatechin-7--D-glucuronide, 4′­O­methyl(−)-
epicatechin-3′--D-glucuronide, and 3′-O-ethyl(−)epicatechin (recovery standard) were 
provided by Mars Incorporated (Hackestown, NJ). (−)-Epicatechin and sulfatase and 
-glucuronidase enzymes were purchased from Sigma (Saint Louis, MI). Water, N,N-
dimethylformamide, methanol and acetonitrile HPLC grade were purchased from Fisher 
(Pittsburgh, PA). 
 
Sample preparation for the identification and quantification of individual (−)-
epicatechin metabolites in human plasma 
The sample preparation method was adapted from Unno et al. [32] and further 
developed. 1 ml of plasma was spiked with 50 µl of a solution containing 10 µM 
3′­O­ethyl(−)­epicatechin (recovery standard) and diluted with 2 ml of 3.4% (w/v) of 
phosphoric acid. Thereafter, samples were loaded onto solid phase extraction (SPE) 
cartridges (Oasis HLB 60 mg, 3 cc) previously conditioned with 1 ml of N,N-dimethyl 
formamide (DMF):methanol (7:3) and 0.5% (v/v) acetic acid in water. The washing steps 
consisted of 3 ml of 0.5% (v/v) acetic acid in water, 1 ml of water:methanol:acetic acid 
(80:20:0.5) and 1 ml of 0.5% (v/v) acetic acid in acetonitrile. For elution, cartridges were 
dried and eluted with the addition of 1 ml of DMF:methanol (7:3) twice. The eluate was 
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collected in tubes containing 200 µl of 0.5% (v/v) acetic acid in methanol. The total 
volume was reduced to approximately 50 µl using a speedvac concentrator (Thermo 
Electron Corp., SPD131DDA-115) at 2-3 mmHg of pressure and refrigerated vapor trap 
(Thermo Electron Corp., RVT4101-115) working at -100°C . Samples were then mixed 
with a solution containing 75 pmols of catechol and 300 pmols of resorcinol (internal 
standards) and analyzed by HPLC within 24 h.  
To determine the extraction efficiency (i.e. recovery) of (−)-epicatechin metabolites, 
plasma samples were spiked with increasing concentration of the (−)-epicatechin 
metabolites to generate final concentrations ranging from 10 to 1000 nM. These samples 
were analyzed applying the method described above. For comparison purposes, plasma 
samples spiked with select (−)-epicatechin metabolites were analyzed using a different 
sample conditioning method which was based on a protein precipitation with methanol 
as described elsewhere [35]. 
 
Sample preparation for the quantification of (−)-epicatechin metabolites in human 
plasma using differential hydrolysis. 
To assess the presence of those (−)-epicatechin metabolites for which we do not 
have standards and to further compare the results obtained using the direct 
quantification of individual metabolites, we quantified (−)-epicatechin metabolites in 
plasma using differential hydrolysis. This method is based on the treatment of plasma 
samples with aryl-sulfatase (aSL) and -glucuronidase (GL) enzymes that specifically 
hydrolyze (−)-epicatechin sulfates and glucuronides, respectively, giving rise to (−)-
epicatechin, 3′-O-methyl(−)epicatechin and 4′-O-methyl(−)epicatechin that are later 
quantified in the samples. Using this approach it is possible to identify the following 
groups of (−)-epicatechin metabolites: (−)-epicatechin glucuronides, 3′-O-methyl(−)-
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 9 
epicatechin glucuronides, 4′-O-methyl(−)-epicatechin glucuronides, (−)-epicatechin 
sulfates and 3′-O-methyl(−)-epicatechin sulfates and 4′-O-methyl(−)-epicatechin sulfates. 
To select suitable aSL and GL enzymes to be used in this study, we compared the 
extent of hydrolysis of surrogate O-glucuronidated and O-sulfonated metabolites (4-
nitrophenyl--D-glucuronide and nitrocatechol sulfate, respectively) in plasma using 
aSLs and GLs from: i) Helix pomatia (13.1 kIU/ml of GL and 0.32 kIU/ml of aSL), ii) 
agglutinin-free Helix pomatia (9.0 kIU/ml of GL and 0.04 kIU/ml of aSL), iii) E. coli (9.8 
kIU/ml of GL) and Abalone entrails (0.14 kIU/ml of aSL), and iv) Patella vulgate (22.1 
kIU/ml of GL and 0.39 kIU/ml of aSL) (Fig. 1). The results obtained demonstrated that 
that aSL and GL from Helix pomatia exerted a complete hydrolysis of the surrogate 
metabolites. In addition, these enzymes were capable of hydrolyzing a series of 
authentic (−)-epicatechin metabolite standards, including (−)-epicatechin-4′­sulfate, (−)-
epicatechin-7--D-glucuronide, 3′­O­metyl(−)-epicatechin-7--D-glucuronide, 
4′­O-methyl(−)-epicatechin-5--D-glucuronide, 4′­O­metyl(−)-epicatechin-7--D-
glucuronide and 4′­O­metyl(−)-epicatechin-3′--D-glucuronide (data not shown). 
Importantly, -glucuronidase from bovine liver, while effective in catalyzing the complete 
hydrolysis of O-glucuronidated metabolites, O-sulfates remained unaffected by these 
enzymes. 
The quantification of (−)-epicatechin, 3′-O-methyl(−)epicatechin, and 4′-O-
methyl(−)epicatechin in plasma was determined in 0.5 ml of plasma that was spiked with 
50 µl of a solution containing 10 µM 3′­O­ethyl(−)­epicatechin (recovery standard), 
acidified with 50 µl of 1.2 M acetic acid and incubated for 40 min at 37°C in the presence 
of 5,000 IU of -glucuronidase and at least 150 IU of aSL from Helix Pomatia or 5,000 IU 
of GL from bovine liver. Thereafter, samples were put on ice, diluted with 1.3 ml of 
0.5% (v/v) acetic acid in water and centrifuged for 15 min at 16,500xg at 4°C. Finally, 
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samples loaded onto SPE cartridges following the same protocol as for the 
determination of individual metabolites, with the exception of the second washing step 
that was done using 1 ml of water:methanol:acetic acid (70:30:0.5).  
To determine the extraction efficiency (i.e. recovery) of (−)-epicatechin, 3′-O-
methyl(−)epicatechin and 4′-O-methyl(−)epicatechin, plasma samples containing aSL 
and GL from Helix pomatia were spiked with increasing concentrations of the above 
metabolites to generate final concentrations ranging from 10 to 1000 nM. These samples 
were incubated for 40 min at 37°C and analyzed using the method described above. For 
comparison purposes, plasma samples spiked with the same compounds were analyzed 
using a different sample conditioning method, which was based on a protein precipitation 
with methanol as described elsewhere [35].  
 
Chromatographic conditions for the quantification of (−)-epicatechin metabolites 
(−)-Epicatechin and its related metabolites were resolved and quantified using an Agilent 
HPLC 1100 series equipped with a quaternary pump, autosampler, column and sample 
thermostat, UV/Vis (UVD) and fluorescence detectors (FLD) and an ESA Coulochem 
Array Detector (ECD), model 5600A equipped with a cell model 6210 with an array of 4 
electrodes. Chromatography was based on a Phenomenex Luna C-18(2) column (150 x 
4.6 mm, 3 µm particle size) with guard column. The separation and resolution of 
compounds was achieved using the elution program as described by Ottaviani et al. [35]. 
The detection of (−)-epicatechin and its related metabolites was done following the 
traces of fluorescence at 276 nm excitation and 316 nm emission, UV absorption at 280 
nm and oxidation at 225 mV, 350 mV, 425 mV and 550 mV.  
 
Identification of individual metabolites using HPLC-MS/MS and enzymatic 
hydrolysis 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11 
Peaks designated as potential SREMs were initially identified based on a retention time 
comparison with authentic (−)-epicatechin metabolite standards, fluorescence emission 
spectra (from 301 to 400 nm), UV-absorbance spectra (from 200 to 400 nm), the ratio of 
fluorescence- vs. UV intensity, and electrochemical detection (at 225 mV, 350 mV, 425 
mV and 550 mV). To further substantiate the identity of the metabolites detected, 
samples from different subjects were analyzed using the chromatographic conditions 
described above, and the putative SREM peaks were collected. An aliquot of the 
collected fractions was incubated in the presence of aSL or GL enzymes, and the 
products of hydrolysis were analyzed by HPLC as described above. Other aliquots of 
collected fractions were analyzed by HPLC-MS/MS, using an Agilent HPLC 1100 series 
LC equipped with a Metachem Polaris C18-A column (4.6x250 mm, 3 µm particle size) 
coupled to a AB Sciex API 4000 QTrap mass spectrometer with a turbo ion spray source 
in negative ion mode. AB Sciex Analyst version 1.5 software was used for data 
analyses. The chromatographic conditions consisted of a linear gradient from A to B at 
constant flow rate of 0.5 ml/min starting with 100% A for 1 min, continuing with a linear 
increase of B up to 100% in 25 min and maintaining 100% B for 1 more min; where A 
was 10 mM ammonium acetate in water:acetonitrile (95:5) and B was 10 mM ammonium 
acetate in water:acetonitrile (5:95). The identification of (−)-epicatechin metabolites was 
conducted with the following m/z transition: 369289 (epicatechin sulfates); 465289 
(epicatechin glucuronides), 383289 and 383303 (O-methylepicatechin sulfates); 
479113 (O-methylepicatechin glucuronides), 305109 (O-methylepicatechin) and 
289109 (epicatechin). The ion spray and orifice voltages, temperature, and collision 
energy were set at -4200 V, -65 V, 500°C, and -36 V, respectively. The collision gas 
(nitrogen) was maintained at the medium setting. Data acquisition was conducted using 
multiple reaction monitoring (MRM) with a 75 ms dwell time per transition. 
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Human Study I: identification and quantification of (−)-epicatechin metabolites in 
circulation 
(−)-Epicatechin-containing test drink: the test drink consisted of a cocoa dairy-based 
drink containing (−)-epicatechin in addition to other flavanols and procyanidins. The 
amount of the test compound consumed by each participant was identical in terms of 
amount per kg of body weight (BW). The test drink was prepared by mixing 0.5 g/kg BW 
of a low-flavanol cocoa powder, 5 g/kg BW of milk (1% fat) and 22 mg/kg BW of a cocoa 
extract containing 47.7% (w/w) of flavanols and procyanidins (as determined using the 
method detailed in [36]. The resulting amount of (−)-epicatechin consumed with the drink 
was 1.8 mg of (−)-epicatechin/kg of BW. The content of macro-nutrients, caloric load, as 
well as the amounts of theobromine, caffeine and other flavanols and procyanidins in the 
drink are listed in table 1. This drink was similar in composition to flavanol-rich drinks 
that have been reported to induce an acute vascular response in humans after 
consumption [10, 13]. The cocoa extract (Cocoapro® processed cocoa extract) and the 
low-flavanol cocoa powder were supplied by Mars Incorporated (Hackettstown, NJ, 
USA). 
 
Participants: We screened healthy male volunteers between 18 and 35 years of age. 
Main exclusion criteria were a body mass index (BMI) higher than 30 kg/m2, a history of 
cardiovascular, renal or liver disease, gastrointestinal disorders and previous 
gastrointestinal surgery, smoking during or within the last 5 years from the initialization of 
the study, current consumption of herbal, antioxidant or vitamin supplements and 
existing allergies to peanuts and milk. To reduce the contribution of flavanols from the 
diet, participants were asked to follow a low-flavanol diet on the day before, and during 
the study days. All volunteers were instructed on how to follow a low-flavanol diet, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 13 
receiving a list of suggested foods containing low or negligible amounts of flavanols. In 
addition, we provided the volunteers with flavanol-free foods for their supper on the day 
prior to the study day, as well as for all the meals during the study day. Volunteers were 
asked to restrain from consuming alcohol, coffee or other caffeine-containing beverages, 
on the day prior to, and during the study visits. Volunteers were asked to fast for 12 h 
before each study day (water ad libitum). 
 
Study design: Upon arrival, volunteers (n=10) received 4 g/kg BW of drinking water to 
control for the level of hydration. One h later, volunteers were given the test drink and 
were asked to consume it within 5 min. Venous blood samples were taken using EDTA-
containing Vacutainers at 0 h (before intake), and 1 h, 2 h and 4 h after drink ingestion. 
Plasma was obtained by whole blood centrifugation at 1800xg for 15 min at 4°C, 
separated into aliquots, and spiked with ascorbic acid (final concentration: 1 mg/ml). 
Plasma samples were stored at -80°C until analysis.  
Volunteers participated in the study on different days, and the study was completed in 4 
weeks. This study protocol was approved by the Institutional Review Board of the 
University of California Davis, and all subjects gave their written informed consent to 
participate.  
 
Human Study II: comparison of (+) and (−)-epicatechin metabolites in circulation 
To compare the profile of SREM after the consumption of (+) and (−)-epicatechin we re-
analyzed samples that were originally generated from a study aimed at investigating the 
effect of flavanol stereochemistry on absorption and O-methylation  [35]. While the latter 
investigation did not concern itself with assessing the O-sulfonated and O-
glucuronidated metabolites, a re-probing of the plasma samples collected can provide 
valuable insights with regard to the stereochemistry-specific aspects of flavanol 
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sulfonation and  glucuronidaton.  This re-analysis was limited to samples collected 2 h 
after the consumption of 1.5 mg/kg of BW of (−)- and (+)-epicatechin in healthy adult 
humans [n=7]. For further details on the study design, test drink and study group, please 
refer to [35]. 
 
Statistical analysis 
The primary test for an effect was a test of the interaction in a two-way repeated 
measures ANOVA (where the factors were time and the different metabolites). The 
ANOVA and Tukey P values as well as the Pearson-product motion correlation 
coefficient (r) were computed with SigmaStat 3.5 (Systat Software Inc, San Jose, CA, 
USA). P-values of 0.05 or less were considered statistically significant. To compare 
variances of the recoveries obtained with SPE and protein precipitation, we used the F 
test for equal variance. P<0.05 indicated that variances of both groups are not equal. 
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Results 
Characterization of (−)-epicatechin metabolite standards, sample preparation 
method and the HPLC detection systems used. 
For this study we used a total of 12 authentic (−)-epicatechin metabolite standards. The 
chemical identity of these standards is supported by an unambiguous de novo chemical 
synthesis and by 1H-NRM, 13C-NMR and mass spectrometric analysis (Supplementary 
data; supplementary Scheme I, and supplementary Fig. 1-3. Additionally, we present 
HPLC chromatogram traces demonstrating the resolution and detection of all 12 (−)-
epicatechin metabolite standards using UVD, FLD and ECD as described in ‘material 
and methods’ (Fig. 2). While all of the metabolite standards can be detected following 
UV-absorbance at 280 nm, the detectability of these compounds based on FLD and 
ECD methods varied significantly. For instance, metabolites bearing a free catechol 
group were detected with high sensitivity and selectivity using ECD at an 
electrochemical potential of 225 mV (Fig. 2). Conversely, metabolites with a conjugated 
catechol group were only detected at higher potentials (550 mV). While most metabolite 
standards were detected using FLD, (−)-epicatechin sulfates exhibited a very low 
fluorescence signal, and therefore were unquantifiable by this detection method. The 
optimal conditions identified for the quantification of each of (−)-epicatechin metabolite 
standards investigated in this study are listed in table 2. 
Additionally, this series of (−)-epicatechin metabolite standards were used to 
determine the extraction efficiency (i.e. recovery) of these compounds from plasma 
using a solid-phase extraction method, as described in the materials and method 
section. The recoveries obtained for this series of (−)-epicatechin metabolite standards 
ranged from 74 to 100% (Table 2). Importantly, these recoveries were higher (pair-t test; 
p<0.001) and less variable (F test; p<0.05) than the recoveries obtained by employing a 
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more commonly used sample conditioning method based on a plasma protein 
precipitation approach with methanol (Table 2). 
 
Study population 
Basic biometric characteristics of the study group participating in Study I are 
presented in table 3. Baseline flavanol concentrations in plasma were below the limit of 
detection on each study day, indicating compliance with the flavanol-low diet as detailed 
in the study protocol. Volunteers reported no adverse events associated with their 
participation in this study. For details on the study group participating in Study II, please 
refer to reference [35]. 
 
Determination of the identity and concentration of individual (−)-epicatechin 
metabolites in humans 
Oral ingestion of the test drink resulted in the absorption of (−)-epicatechin and 
the subsequent occurrence of different SREM in plasma (Fig. 3 and 4). Despite the fact 
that (−)-epicatechin O-glucuronidation could theoretically occur at 5 different sites on the 
(−)-epicatechin molecule, one single predominant (−)-epicatechin glucuronide was 
detected in plasma. This metabolite corresponded to epicatechin-3′--D-glucuronide 
(Fig. 3B). The identity of this metabolite was confirmed by further analysis of the 
collected peak by HPLC-MS/MS (peak detected at m/z 465289) and differential 
enzymatic hydrolysis (GL sensitive; product of hydrolysis: (−)-epicatechin). The 
maximal plasma concentration of epicatechin-3′--D-glucuronide (589±85 nM; p<0.05) 
was reached within 2 h after the consumption of the test drink. Additionally, we also 
detected the presence of significantly smaller amounts of O-methylated epicatechin 
glucuronides, particularly 4′-O-methyl(−)-epicatechin-7--D-glucuronide. This 
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observation remained qualitative, as the levels of this metabolite were below the limit of 
quantification (~20 nM for this compound). 
Regarding the (−)-epicatechin sulfates, we observed the presence of 3 distinct 
metabolites in plasma (Fig. 4B). The most abundant compound of this series, (−)-
epicatechin-3′-sulfate, reached a maximal plasma concentration of 331±26 nM at 2 h 
after consumption. The other two sulfates corresponded to (−)-epicatechin-5-sulfate and 
(−)-epicatechin-7-sulfate, both of which presented significantly lower plasma levels (37±3 
nM and 12±1 nM, respectively) as compared to (−)-epicatechin-3′-sulfate. The identity of 
these (−)-epicatechin derivatives was also verified via the collection of HPLC fractions 
and further analysis by HPLC-MS/MS (peaks detected at m/z 369289) and enzymatic 
hydrolysis (aSL sensitive; product of hydrolysis: (−)-epicatechin). Furthermore, we also 
observed the presence of at least 4 peaks that were collected by HPLC and analyzed by 
HPLC-MS/MS (peaks detected at m/z 383303) and enzymatic hydrolysis (aSL 
sensitive; product of hydrolysis: 3′-O-methyl(−)-epicatechin [peaks i and ii] and 4′-O-
methyl(−)-epicatechin [peaks iii and iv]). Therefore, the results obtained support the 
notion that these compounds represent two individual 3′-O-methyl(−)-epicatechin 
sulfates (peaks i and ii) and two distinct 4′-O-methyl(−)-epicatechin sulfates (peaks iii 
and iv), respectively (Fig. 4B). Supporting this conclusion, further analyses with authentic 
3′-O-methyl(−)-epicatechin sulfates standards, demonstrated that sulfonation of the 
metabolites represented by peaks i and ii occurred in position O5 and O7, respectively.  
 
Unmetabolized (−)-epicatechin was present in circulation at low concentrations, 
reaching a maximum of 4±1 nM at 1 h after test drink consumption. No free 3′/4′-O-
methy(−)-epicatechin was detected. 
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Corresponding determination of plasma (−)-epicatechin metabolites using 
differential hydrolysis 
Corroborating the results detailed above, the analysis of plasma samples using 
differential hydrolysis also identified (−)-epicatechin glucuronides and (−)-epicatechin 
sulfates as major constituents of the metabolome of (−)-epicatechin in humans (Fig. 5A). 
The levels reached by (−)-epicatechin glucuronides were maximal 2 h after consumption, 
presenting values of 573±77 nM (p<0.05). The concentration of (−)-epicatechin 
glucuronides as determined by differential hydrolysis was not significantly different from 
the concentration of (−)-epicatechin-3′--D-glucuronide as assessed using authentic 
standards (r=0.995 and a slope of 1.03±0.02; p<0.001; Fig. 5B). The group of (−)-
epicatechin sulfates reached a maximal plasma level of 301±30 nM at 2 h after 
consumption that was not significantly different from the sum of (−)-epicatechin-3′-
sulfate, (−)-epicatechin-5-sulfate and (−)-epicatechin-7-sulfate as assessed using 
authentic standards (r=0.952 and a slope of 1.12±0.03; p<0.001; Fig. 5B). In addition, 
the use of differential hydrolysis permitted the identification and quantification of two 
other groups of (−)-epicatechin metabolites, namely the 3′ and 4′-O-methyl(−)-
epicatechin sulfates. In this case, the maximal levels of 3′-O-methyl(−)-epicatechin 
sulfates were 214±26 nM at 2 h after consumption (p<0.05), while the group of 4′-O-
methyl(−)-epicatechin sulfates presented plasma levels of 51±8 nM (p<0.05). 
Concurring with the findings using (−)-epicatechin metabolite standards, the 
levels of 3′ and 4′-O-methylated (−)-epicatechin glucuronides represented a negligible 
fraction of the SREM in humans, presenting values below 20 nM in plasma. No O-
sulfonated and O-glucuronidated (−)-epicatechin metabolites were detected in the 
samples. 
 
Relative abundance of (−)-epicatechin metabolites in humans 
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Combining the data that emanated from the use of differential hydrolysis with the 
data obtained using authentic standards, we are able to detect and measure 8 distinct 
postprandial metabolites of (−)-epicatechin in human plasma. The identity of all 8 
metabolites was further supported by HPLC-MS/MS. The most abundant (−)-epicatechin 
metabolite was (−)-epicatechin-3′--D-glucuronide, which accounted for 46±6% of all 
epicatechin metabolites detected in plasma at 2 h after consumption (Fig. 6). The 
respective abundance of (−)-epicatechin-3′-sulfate, (−)-epicatechin-5-sulfate, and (−)-
epicatechin-7-sulfate was 28±6%, 3.1±0.8% and 1.1±0.3% of all epicatechin metabolites 
identified (Fig. 6). The group of 3′ and 4′-O-methyl(−)-epicatechin-5/7-sulfates presented 
a relative abundance of 17±2% and 4.3±0.7%, respectively (Fig. 6).  
 
Influence of the stereochemical configuration of epicatechin on its metabolic fate 
in humans 
We also investigated the influence of flavanol stereochemistry on the metabolic 
profile of the postprandial profile of SREM following the ingestion by humans of (−)-
epicatechin and (+)-epicatechin, respectively. As depicted in figure 8, the concentrations 
as well as relative abundance of individual metabolites detected in plasma were highly 
dependent on the stereochemical configuration of the epicatechin ingested. While 
epicatechin-3′--D-glucuronide was the only O-glucuronidated metabolite identified in 
plasma regardless of the epicatechin enantiomer consumed, the maximal plasma 
concentration of this compound reached 336±75 nM after (−)-epicatechin consumption, 
but only 13±7 nM after the ingestion of (+)-epicatechin (Fig. 7). Analogously, the 
concentration detected for epicatechin-3′-sulfate (377±49 nM) after (−)-epicatechin 
consumption was almost 4 times higher than the concentration detected for the same 
metabolite after (+)-epicatechin consumption (101±13 nM, p<0.05; Fig. 7). In contrast, 
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epicatechin-5-sulfate, which reached a level of 50±6 nM after (−)-epicatechin intake, was 
extant at a concentration of 270±29 nM after (+)-epicatechin consumption (p<0.05; Fig. 
7), representing a 5 fold difference in favor of the (+) enantiomer. 
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Discussion 
In the present study, we developed a method for the analysis of the postprandial 
profile of SREM in human plasma samples. This method was subsequently employed to 
assess (−)-epicatechin absorption and metabolism after the consumption of a well 
characterized and standardized flavanol- and procyanidin-containing cocoa drink. Our 
work resulted in the identification of the chemical structure, plasma concentration, and 
relative abundance of the majority of SREM systemically present in humans. 
The development and testing of our method using a wide range of de novo 
chemically synthesized (−)-epicatechin metabolite standards resulted not just in novel 
insights into flavanol metabolism, but also in the identification of important limitations 
associated with analytical methods in current use. For instance, the wide variation in 
sample conditioning/preparation methods, including methods of plasma protein 
precipitation [35], is an important contributing factor to the widely varying yields in 
extraction efficiencies (recoveries), and therefore also to the differences in the reported 
relative abundance of individual metabolites. For example, testing a range of currently 
utilized sample preparation procedures, our data demonstrated differences in the 
recovery of (−)-epicatechin-3′--D-glucuronide that ranged from 28% to 74% (Table 2). 
In addition, the low fluorescence signal yielded by (−)-epicatechin sulfates, especially 
evident in the case of (−)-epicatechin-3′-sulfate, could explain why previous 
investigations that exclusively relied on FLD detection systems were unable to detect, 
and thus to recognize these metabolites as a significant part of the (−)-epicatechin 
metabolome in humans [17, 22]. Finally, it is also worth mentioning the considerable 
limitations associated with the use of aSL and GL to assess (−)-epicatechin levels and 
metabolism. In this context, we detected significant differences in the extent of hydrolysis 
of sulfates depending on the origin of the enzymes utilized (Fig. 1). The limitations of 
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using  aSL and  GL enzymes is also supported by previous reports suggesting that 3′- 
and 4′-O-methyl(−)-epicatechin sulfates are more resistant to hydrolysis [37]. 
Consequently, these data indicate that the sole dependency on enzymatic hydrolysis 
may lead to an underestimation of the circulating levels of (−)-epicatechin metabolites, 
which should be considered as a limitation of data sets generated by using this 
methodological approach. Taken together, the results presented here clearly 
demonstrate that the current ambiguity in the scientific literature with regard to (−)-
epicatechin levels and metabolism in mammals can be attributed, at least in part, to the 
significant differences in various aspects of the analytical methods employed. In this 
context, we hope that the present study may contribute towards the building of a 
consensus with regard to the analytical methodology used to assess the identity and 
concentration of (−)-epicatechin metabolites in humans. 
The application our method in the context of a human dietary intervention study 
resulted in the identification, verification, and measurement of 8 individual (−)-
epicatechin metabolites, consisting of (−)-epicatechin-3′--D-glucuronide, (−)-
epicatechin-3′-sulfate, (−)-epicatechin-5-sulfate and (−)-epicatechin-7-sulfate. Moreover, 
we described the presence of 4 distinct 3′- and 4′-O-methyl(−)-epicatechin sulfates, each 
of which is sulfonated in either position O5 or O7 of the epicatechin molecule. 
Our findings demonstrate that (−)-epicatechin-3′--D-glucuronide is the most 
predominant O-glucuronidated metabolic derivative of (−)-epicatechin present in the 
human circulation. These results are supported by previous quantitative or semi- 
qualitative observations by Natsume et al. who originally described this metabolite in 
humans [21], and by more recent qualitative observations of a single O-glucuronidated 
(−)-epicatechin metabolite present in plasma after the consumption of different (−)-
epicatechin-containing products [23, 24, 38]. Unlike O-glucuronidation, (−)-epicatechin 
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O-sulfonation resulted in a more diverse group of metabolites in humans. While in the 
present study, a structural identification of 3 distinct (−)-epicatechin sulfates is provided 
for the first time, Auger et al. previously reported on the presence of 3 O-sulfonated (−)-
epicatechin derivatives, the structures of which were not further elucidated [23]. 
Collectively, these findings substantiate the notion that O-sulfonation is a key 
conjugating reaction in the metabolism of (−)-epicatechin in humans, resulting in (−)-
epicatechin-3′-sulfate as the most abundant derivative of this series, and one of the most 
abundant (−)-epicatechin metabolites in humans. Furthermore, we clearly demonstrated 
that (−)-epicatechin O-methylation in humans occurs primarily in position 3′ of the (−)-
epicatechin molecule, as is in accordance with the catalytic properties of catechol O-
methyl transferase [39]. Finally, we showed that (−)-epicatechin O-methylation is mainly 
extant in combination with O-sulfonation, and not with O-glucuronidation, as suggested 
in earlier investigations by our group and others [17, 21, 22, 31, 40]. In this context, it is 
noteworthy that previous studies describing the presence of O-methyl(−)-epicatechin 
glucuronides [21] administered (−)-epicatechin in amounts approximately 10 times 
higher than consumed in the present study (ca. 20 mg/kg of BW vs. 1.8 mg/kg of BW), 
suggesting the potential for (−)-epicatechin being subjected to different metabolic 
pathways when consumed in quantities that greatly exceed those relevant in a dietary 
context. Such a concept would also be supported by previous findings on the 
metabolism of mono-phenolic compounds in rats that also describe an amount-
dependent shift in O-sulfonation and O-glucuronidation [41, 42]. In addition, other 
studies identifying the presence of O-methyl(−)-epicatechin glucuronides in circulation 
were conducted in rats [31, 40], also indicating the potential for species-dependent 
differences in the metabolism of (−)-epicatechin. Taken together, it is tenable to 
conclude that in humans, the consumption of diet-relevant amounts of (−)-epicatechin 
leads to the presence in systemic circulation of three predominant and structurally-
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related metabolites, including (−)-epicatechin-3′--D-glucuronide, (−)-epicatechin-3′-
sulfate, and a 3′-O-methyl(−)-epicatechin-5/7-sulfate ( Fig. 8). Nonetheless, to establish 
the limits of validity of these findings and to allow their population-based interpretation, 
future investigations should address inter-individual differences in (−)-epicatechin 
metabolism due to: a) differences in intake amount, food matrix, and consumption 
frequency; b) variations in age, sex, race, dietary- and genetic background; and c) the 
influence of pathophysiological states and medications. 
In the context of our investigations into the role of the stereochemical configuration as a 
determinant of flavanol metabolism, our results were somewhat unexpected. While the 
intake of (+)-epicatechin resulted almost exclusively in the formation of O-sulfonated 
derivatives, the main (−)-epicatechin metabolites included both, O-sulfonated and O-
glucuronidated derivatives. Moreover, while sulfonation of (+)-epicatechin took place in 
position O5, (−)-epicatechin was predominantly sulfonated in the O3′ position. Thus, 
these findings unequivocally demonstrate that the stereochemical configuration of 
flavanols represents a major aspect determining the resulting structure of flavanol 
metabolites in humans. These findings go beyond previous results reported by our group 
that demonstrated stereoisomer-specific differences in the O-methylation of flavanols in 
humans [35]. In addition, our data demonstrate that the majority of (−)-epicatechin 
metabolites identified in this study were those with a conjugated catechol ring. As the 
catechol ring is often referenced as critical element in structure-activity relationships, 
especially with regard to the putative in vivo antioxidant properties of flavanols [43], the 
fact that this structure undergoes significant metabolic derivatization argues for a critical 
review of current assumptions in this direction. 
Overall, the results from the current study provide a detailed description of the systemic, 
postprandial profile of SREM in humans, thus identifying tenable candidate compounds 
that may represent the bioactive principles in a causality chain linking the intake of 
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flavanol-containing foods and the observed biological effects. Consequently, these data 
are thus relevant when investigating the potential molecular targets and the 
mechanisms-of-actions of dietary flavanols and procyanidins in vivo.
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Figure Legends 
Fig. 1: Extent of hydrolysis of O-glucuronidated and O-sulfonated metabolites in plasma. 
Hydrolysis catalyzed by -glucuornidase (GL) and aryl-sulfatase (aSL) enzymes from i) 
Helix pomatia, ii) agglutinin-free Helix pomatia, iii) E. coli  and Abalone entrails, and iv) 
Patella vulgate. Data are expressed as mean ± SEM of the percentage (%) of the 
metabolites hydrolyzed. *p<0.01, significantly different from the control (100% 
hydrolysis). 
 
Fig. 2: Chromatogram traces of de novo synthesized authentic (−)-epicatechin 
metabolite standards. Detection with UV absorbance (UVD), fluorescence (FLD), and 
electrochemical detection (ECD) at 225 mV and 550 mV, where [A] is (−)-epicatechin-7-
-D-glucuronide, [B] is 3′­O­methyl(−)-epicatechin-7--D-glucuronide, [C] is (−)-
epicatechin-3′--D-glucuronide, [D] is 4′­O­methyl(−)-epicatechin-5--D-glucuronide, [E] 
is (−)-epicatechin-5-sulfate, [F] is 4′­O­methyl(−)-epicatechin-7--D-glucuronide, [G] is 
4′­O­methyl(−)-epicatechin-3′--D-glucuronide, [H] is (−)-epicatechin-7-sulfate, [I] is (−)-
epicatechin , [J] is (−)-epicatechin-3′­sulfate, [K] is 3′-O-methyl(−)epicatechin, [L] is 4′-O-
methyl(−)epicatechin, and [RS] is 3′-O-ethyl(−)epicatechin. Insert: chemical structure of 
the authentic (−)-epicatechin metabolites standards used in the present study that 
include metabolites derived from O-methylation (-CH3), O-glucuronidation (-Gluc
-) and 
O-sulfonation (-SO3
-) in four different positions in the molecule O4′ (R1), O3′ (R2), O5 (R3) 
and O7 (R4). 
 
Fig. 3: Circulating (−)-epicatechin glucuronides. A) Level of individual (−)-epicatechin 
glucuronides in plasma after the consumption of a test drink containing 1.8 mg/kg of BW 
of (−)-epicatechin. Data are expressed as average ± SEM [n=10] in nM. B) 
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Chromatogram traces (FLD detection) of authentic (−)-epicatechin glucuronide 
standards and plasma samples obtained before (0 h) and 2 h after the consumption of 
the test drink, where [A] is (−)-epicatechin-7--D-glucuronide, [B] is 3′­O­methyl(−)-
epicatechin-7--D-glucuronide, [C] is (−)-epicatechin-3′--D-glucuronide, [D] is 
4′­O­methyl(−)-epicatechin-5--D-glucuronide, [F] is 4′­O­methyl(−)-epicatechin-7--D-
glucuronide and [G] is 4′­O­methyl(−)-epicatechin-3′--D-glucuronide. 
 
Fig. 4: Circulating (−)-epicatechin sulfates. A) Level of individual (−)-epicatechin sulfates 
in plasma after the consumption of a test drink containing 1.8 mg/kg of BW of (−)-
epicatechin. Data are expressed as average ± SEM [n=10] in nM. B) Chromatogram 
traces (ECD detection) of authentic (−)-epicatechin sulfate standards and plasma 
samples obtained before (0 h) and 2 h after the consumption of the test drink, where [E] 
is (−)-epicatechin-5-sulfate, [H] is (−)-epicatechin-7-sulfate, [I] is (−)-epicatechin, [J] is 
(−)-epicatechin-3′­sulfate, and where [i] and [ii] were assigned as 3′­O­methyl(−)-
epicatechin-5–sulfate and  3′­O­methyl(−)-epicatechin-7–sulfate, respectively, and [iii] 
and [iv] were assigned as 4′­O­methyl(−)-epicatechin-5/7-sulfates. 
 
Fig. 5: Postprandial (−)-epicatechin metabolites in plasma. A) Level of different groups of 
(−)-epicatechin metabolites in plasma after the consumption of a test drink containing 1.8 
mg/kg of BW of (−)-epicatechin. Data are expressed as average ± SEM [n=10] in nM. 
*significantly different from the levels determined at the rest of the time points within the 
same group of metabolites, p<0.05. B) Correlation between the levels of (−)-epicatechin-
3′--D-glucuronide and the levels of (−)-epicatechin glucuronides determined with 
differential hydrolysis in plasma (r=0.995, slope of 1.03±0.02; p<0.001) and between the 
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sum of individual (−)-epicatechin sulfates and the levels of (−)-epicatechin sulfates 
determined with differential hydrolysis in plasma (r=0.951, slope of 1.13±0.02; p<0.001).  
 
Fig. 6: Relative amounts of individual (−)-epicatechin metabolites in plasma. Data 
represent SREM profile at 2 h after the consumption of a test drink containing 1.8 mg/kg 
of BW of (−)-epicatechin. *The abundance of these metabolites was calculated 
according to the concentration determined by differential hydrolysis. 
 
Fig. 7: Stereochemistry-dependent epicatechin metabolism. Level of individual 
epicatechin metabolites in plasma after the consumption of a cocoa drink containing 1.5 
mg/kg of BW of (−)-epicatechin or 1.5 mg/kg of BW of (+)-epicatechin, respectively. Data 
are expressed as average ± SEM [n=7] in nM. *significantly different from the levels 
reached after (−)-epicatechin consumption within the same metabolite, p<0.05 
 
Fig. 8: Schematic representation of the main circulating SREM. Based on assessments 
in healthy males after the consumption of diet-relevant amounts (−)-epicatechin. UGT: 
UDP-glucuronosyltransferase, SULT: sulfotransferase, COMT: catechol O-methyl 
transferase.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 36 
Tables 
Table 1: Composition of the test drink used in study I. Values represent the amounts that 
would have been consumed by a 75 kg subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nutritional details Amount received 
Calories (kcal) 224 
Total fat (g) 19 
Saturated fat (g) 3 
Cholesterol (mg) 19 
Total carbohydrates (g) 29 
Dietary fiber (g) 3 
Sugars (g) 24 
Caffeine (mg) 35 
Theobromine (mg) 297 
Total flavanols and 
procyanidins (mg) 
1100 
(−)-Epicatechin (mg) 138 
(±)-Catechin (mg) 19 
Procyanidins (dimers to 
decamers) (mg) 
944 
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Table 2: Recovery of (−)-epicatechin metabolites from plasma samples using SPE (as 
described in Materials and Method section) and a protein precipitation method [35]. Data 
are expressed as average ± SEM of the percentage recovered. Additionally, the 
detection system used for quantification for each metabolite is included. n.q. equals not 
quantifiable (because of the presence of interfering peaks in the chromatogram 
introduced via protein precipitation method). 
(−)-Epicatechin metabolites Method 
Recovery (%) 
Detection 
system 
Solid-phase 
Extraction 
Protein 
Precipitation 
(−)-epicatechin 
Direct 
quantification 
of individual 
metabolites 
 
93±1 76±1 ECD 
(−)-epicatechin-7--D-glucuronide 90±2 n.q. ECD/FLD 
(−)-epicatechin-3'--D-glucuronide 74±1 28±3 FLD 
3'-O-methyl(−)-epicatechin-7--D-
glucuronide 
86±4 60±1 FLD 
4'-O-methyl(−)-epicatechin-5--D-
glucuronide 
88±1 59±1 FLD 
4'-O-methyl(−)-epicatechin-7--D-
glucuronide 
101±1 62±1 FLD 
4'-O-methyl(−)-epicatechin-3'--D-
glucuronide 
72±2 49±1 FLD 
(−)-epicatechin-5-sulfate 85±1 n.q. ECD 
(−)-epicatechin-7-sulfate 84±1 n.q. ECD 
(−)-epicatechin-3'-sulfate 70±1 n.q. ECD 
(−)-epicatechin 
Differential 
hydrolysis 
82±1 78±1 FLD 
3'-O-methyl(−)-epicatechin 73±1 109±3 FLD 
4'-O-methyl(−)-epicatechin 78±1 103±2 FLD 
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Table 3: Study I participant characteristics 
 
Parameter (units) Value 
Age (y) 32±1 
Weight (kg) 75±8 
BMI (kg/m2) 24±2 
Systolic blood pressure (mmHg) 123±9 
Diastolic blood pressure (mmHg) 74±8 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 39 
 
E
x
te
n
t 
o
f 
h
y
d
ro
ly
s
is
 o
f 
s
u
rr
o
g
a
te
 m
e
ta
b
o
li
te
s
 (
%
)
0
20
40
60
80
100
120
O-glucuronidated metabolites
O-sulfonated metabolites
Helix pomatia Helix pomatia
agglutinin-free
*
* *
Patella vulgataE. coli
Abalone entralis  
Figure 1 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 40 
Elution time (min)
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Highlight 
 
 Improved sample preparation- and analytical methods for (-)-epicatechin 
metabolites 
 Novel insights into the uptake and metabolism of flavanols in humans 
 Identification & quantification of structurally-related (-)-epicatechin metabolites  
 Stereochemical configuration of flavanols affects their metabolism in humans 
 
